Millennium Management’s Galectin Therapeutics GALT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.23M | Buy |
798,434
+562,926
| +239% | +$1.71M | ﹤0.01% | 3771 |
|
|
2025
Q4 | $980K | Buy |
235,508
+125,086
| +113% | +$659K | ﹤0.01% | 4505 |
|
|
2025
Q3 | $468K | Sell |
110,422
-34,106
| -24% | -$128K | ﹤0.01% | 5117 |
|
|
2025
Q2 | $305K | Buy |
+144,528
| New | +$216K | ﹤0.01% | 5184 |
|
|
2025
Q1 | – | Sell |
-10,108
| Closed | -$13K | – | 6040 |
|
|
2024
Q4 | $13K | Sell |
10,108
-26,264
| -72% | -$62.9K | ﹤0.01% | 5765 |
|
|
2024
Q3 | $100K | Sell |
36,372
-16,943
| -32% | -$41.6K | ﹤0.01% | 5584 |
|
|
2024
Q2 | $120K | Buy |
53,315
+28,234
| +113% | +$85.8K | ﹤0.01% | 5273 |
|
|
2024
Q1 | $59.9K | Sell |
25,081
-2,670
| -10% | -$5.05K | ﹤0.01% | 5663 |
|
|
2023
Q4 | $46.1K | Sell |
27,751
-74,897
| -73% | -$145K | ﹤0.01% | 5492 |
|
|
2023
Q3 | $197K | Sell |
102,648
-35,806
| -26% | -$58.9K | ﹤0.01% | 5132 |
|
|
2023
Q2 | $199K | Buy |
138,454
+6,681
| +5% | +$11.3K | ﹤0.01% | 5120 |
|
|
2023
Q1 | $277K | Sell |
131,773
-129,133
| -49% | -$209K | ﹤0.01% | 4967 |
|
|
2022
Q4 | $295K | Buy |
260,906
+18,959
| +8% | +$25.3K | ﹤0.01% | 5121 |
|
|
2022
Q3 | $394K | Sell |
241,947
-16,576
| -6% | -$31K | ﹤0.01% | 5155 |
|
|
2022
Q2 | $339K | Sell |
258,523
-79,430
| -24% | -$114K | ﹤0.01% | 5265 |
|
|
2022
Q1 | $544K | Sell |
337,953
-67,648
| -17% | -$131K | ﹤0.01% | 5055 |
|
|
2021
Q4 | $840K | Buy |
405,601
+55,265
| +16% | +$158K | ﹤0.01% | 4566 |
|
|
2021
Q3 | $1.36M | Sell |
350,336
-218,354
| -38% | -$740K | ﹤0.01% | 4346 |
|
|
2021
Q2 | $1.82M | Buy |
+568,690
| New | +$2.02M | ﹤0.01% | 4076 |
|
|
2019
Q4 | – | Sell |
-10,161
| Closed | -$37K | – | 4353 |
|
|
2019
Q3 | $37K | Sell |
10,161
-1,784
| -15% | -$6.45K | ﹤0.01% | 4065 |
|
|
2019
Q2 | $50K | Sell |
11,945
-351,527
| -97% | -$1.52M | ﹤0.01% | 3952 |
|
|
2019
Q1 | $1.86M | Buy |
+363,472
| New | +$1.75M | ﹤0.01% | 2458 |
|
|
2018
Q4 | – | Sell |
-112,399
| Closed | -$676K | – | 3882 |
|
|
2018
Q3 | $676K | Buy |
112,399
+20,967
| +23% | +$115K | ﹤0.01% | 3081 |
|
|
2018
Q2 | $582K | Sell |
91,432
-4,348
| -5% | -$21.2K | ﹤0.01% | 3095 |
|
|
2018
Q1 | $454K | Buy |
+95,780
| New | +$446K | ﹤0.01% | 3057 |
|
|
2017
Q3 | – | Sell |
-11,000
| Closed | -$27K | – | 3625 |
|
|
2017
Q2 | $27K | Buy |
+11,000
| New | +$29.3K | ﹤0.01% | 3381 |
|
|
2016
Q2 | – | Sell |
-20,086
| Closed | -$29K | – | 3316 |
|
|
2016
Q1 | $29K | Buy |
20,086
+1,807
| +10% | +$2.43K | ﹤0.01% | 3184 |
|
|
2015
Q4 | $30K | Sell |
18,279
-53,866
| -75% | -$123K | ﹤0.01% | 3333 |
|
|
2015
Q3 | $169K | Buy |
72,145
+5,949
| +9% | +$14K | ﹤0.01% | 3166 |
|
|
2015
Q2 | $181K | Buy |
66,196
+47,370
| +252% | +$143K | ﹤0.01% | 3072 |
|
|
2015
Q1 | $63K | Sell |
18,826
-5,496
| -23% | -$19.6K | ﹤0.01% | 3447 |
|
|
2014
Q4 | $84K | Buy |
24,322
+9,157
| +60% | +$40.5K | ﹤0.01% | 3790 |
|
|
2014
Q3 | $76K | Buy |
+15,165
| New | +$118K | ﹤0.01% | 3569 |
|
|
2014
Q2 | – | Sell |
-70,475
| Closed | -$1.08M | – | 3572 |
|
|
2014
Q1 | $1.08M | Buy |
+70,475
| New | +$1M | ﹤0.01% | 2179 |
|
Other funds holding GALT
VCM
WANY
VFT
Millennium Management's GALT Position: Q1 2026 in Review
Millennium Management increased its Galectin Therapeutics (GALT) stake by 239% in Q1 2026, buying an estimated $1.71M and bringing the position to 798,434 shares worth $2.23M. The position accounts for ﹤0.01% of the portfolio, ranked #3771.
Millennium Management first reported a position in GALT in Q1 2014 and has held it in 34 quarters since. 98 funds tracked by Wall St. Rank hold GALT as of Q1 2026.
- Millennium Management held 798,434 shares of Galectin Therapeutics worth $2.23M as of Q1 2026.
- Millennium Management bought 562,926 Galectin Therapeutics shares in Q1 2026, an estimated $1.71M.
- Galectin Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #3771 holding.
- Millennium Management first reported a position in Galectin Therapeutics in Q1 2014 and has held it in 34 quarters since.
- 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2026.
Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.